Daily curated updates for Xperience+ (US market)
AbbVie's 123rd-Ranked $790M Trading Volume Contrasts with $2.1B Acquisition and $1.9B Licensing Deals in Oncology Expansion AInvest
Botox maker AbbVie raises profit forecast after strong sales of immunology drugs Irish Examiner
Jury sides with Allergan in $56M Botox tech feud Life Sciences Intellectual Property Review
AbbVie unit wins $56 mln in US patent trial against Botox rival Reuters
AbbVie's Allergan wins $56 million in Botox patent fight Crain's Chicago Business
Galderma Unveils Positive Data From Clinical Trial American Spa
Evolus Submits Evolysse Sculpt for FDA Approval, Expanding HA Dermal Filler Portfolio Dermatology Times
Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product Yahoo Finance
Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product Business Wire
Evolus announces commercial launch of Evolysse MSN
Evolus Q2 2025: Unpacking Contradictions in Toxin Demand, Evolysse Launch, and Consumer Sentiment AInvest
Evolus Q2 2025 slides: Filler launch drives market expansion despite earnings miss Investing.com Australia
Evolus Q2 2025 slides: Filler launch drives market expansion despite earnings miss By Investing.com Investing.com South Africa
Evolus Announces Publication of Independent Study in JAMA Dermatology Demonstrating Jeuveau® as a Top Performer Among Leading Neurotoxins Yahoo Finance
Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in France Yahoo Finance
Allergan Botox Patent Fight Set for Trial in July in Delaware USA Herald
AbbVie wins $56M royalty award from Revance in Botox patent infringement case Fierce Pharma
AbbVie Unit Wins $56 Million from Revance Over Botox Patents (1) Bloomberg Law News